High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Biological Psychiatry

• Publication date

  2007-10-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BIOPSYCH.2007.04.001PMID 17662961
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mapping of human cerebral sigma1 receptors using positron emission tomography and [11C]SA4503

  2007cited by this paper
• Phencyclidine-Induced Cognitive Deficits in Mice are Improved by Subsequent Subchronic Administration of Fluvoxamine: Role of Sigma-1 Receptors

  2007cited by this paper
• Stability and course of neuropsychological deficits in manic and depressed bipolar patients compared to patients with Major Depression.

  2007cited by this paper
• Tolerability and safety of fluvoxamine and other antidepressants

  2006cited by this paper
• The sigma1 protein as a target for the non-genomic effects of neuro(active)steroids: molecular, physiological, and behavioral aspects.

  2006cited by this paper
• Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals.

  2006cited by this paper
• A feasibility study of [11C]SA4503-PET for evaluating sigma1 receptor occupancy by neuroleptics: The binding of haloperidol to sigma1 and dopamine D2-like receptors

  2006cited by this paper
• Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.

  2006cited by this paper
• Antidepressant Treatment of Psychotic Major Depression: Potential Role of the σ Receptor

  2005cited by this paper
• Function of sigma1 receptors in Parkinson's disease

  2005cited by this paper
• The role of sigma receptors in depression.

  2005cited by this paper
• Understanding the Role of Sigma-1 Receptors in Psychotic Depression

  2005cited by this paper
• Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview

  2005cited by this paper
• The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: implication for drug abuse.

  2005cited by this paper
• Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond.

  2004cited by this paper
• Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

  2004cited by this paper
• σ-1 Receptor Ligands

  2004cited by this paper
• Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia

  2004cited by this paper
• New approaches to managing psychotic depression.

  2003cited by this paper
• High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography.

  2003cited by this paper
• Psychotic depression and mortality.

  2003cited by this paper
• Functional polymorphisms in the sigma1 receptor gene associated with alcoholism.

  2003cited by this paper
• Sigma1 and dopamine D2 receptor occupancy in the mouse brain after a single administration of haloperidol and two dopamine D2-like receptor ligands.

  2003cited by this paper
• Synthesis and evaluation of 11C- and 18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies.

  2003cited by this paper
• Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia

  2003cited by this paper
• Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.

  2003cited by this paper
• The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities.

  2001cited by this paper
• Regulating ankyrin dynamics: Roles of sigma-1 receptors.

  2001cited by this paper
• Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.

  2001cited by this paper
• Mapping of CNS sigma1 receptors in the conscious monkey: Preliminary PET study with [11C]SA4503

  2001cited by this paper
• Measuring receptor occupancy with PET.

  2000cited by this paper
• In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS sigma1 receptors

  2000cited by this paper
• Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration.

  2000cited by this paper
• In vivo evaluation of [(11)C]SA4503 as a PET ligand for mapping CNS sigma(1) receptors.

  2000cited by this paper
• Ca2+ Signaling via ς1-Receptors: Novel Regulatory Mechanism Affecting Intracellular Ca2+Concentration

  2000cited by this paper
• Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs.

  1999cited by this paper
• Not so selective serotonin reuptake inhibitors.

  1998cited by this paper
• Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology

  1998cited by this paper
• Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia.

  1998cited by this paper
• Using secondary binding properties to select a not so selective serotonin reuptake inhibitor.

  1998cited by this paper
• Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study.

  1998cited by this paper
• Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life

  1998cited by this paper
• Performance evaluation of a large axial field-of-view PET scanner: SET-2400W

  1997cited by this paper
• Fluvoxamine alone in the treatment of delusional depression.

  1996cited by this paper
• Binding properties of SA4503, a novel and selective sigma 1 receptor agonist.

  1996cited by this paper
• Binding properties of SA4503, a novel and selective σ1 receptor agonist

  1996cited by this paper
• Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression.

  1996cited by this paper
• Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data

  1996cited by this paper
• Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain.

  1996cited by this paper
• Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects

  1993cited by this paper
• Single and Multiple Oral Dose Fluvoxamine Kinetics in Young and Elderly Subjects

  1992cited by this paper
• Sigma receptors: biology and function.

  1990cited by this paper
• A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography

  1984cited by this paper

• Safety Concerns, Mechanistic Pathways, and Knowledge Gaps in the Clinical Use of Selective Serotonin Reuptake Inhibitors

  2026cites this paper
• Emerging neurobiological targets in psychiatric treatment.

  2026cites this paper
• Cutamesine attenuates hippocampal damage via sigma-1 receptor activation following oxygen-glucose deprivation in vitro.

  2026cites this paper
• The Efficacy of Fluvoxamine in Anxiety Disorders and Obsessive-Compulsive Disorder: An Overview of Systematic Reviews and Meta-Analyses

  2025cites this paper
• The sigma–1 receptor: a mechanistically–informed therapeutic target for antidepressants

  2025cites this paper
• An Overview of the Systematic Reviews About the Efficacy of Fluvoxamine on Depression

  2025cites this paper
• Sigma-1-targeting multimodal compound HBK-15 reverses memory deficits and restores hippocampal plasticity under NMDA hypofunction.

  2025cites this paper
• A Full-Spectrum Evaluation of Sigma-1 Receptor (S1R) Positron Emission Tomography (PET) Radioligands from Binding Affinity to Clinical Imaging

  2025cites this paper
• Viewpoints Sigma-1 receptor agonist fluvoxamine for multiple sclerosis

  2024cites this paper
• A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications

  2024cites this paper
• Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants

  2024cites this paper
• Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis

  2023cites this paper
• Overview of the potential use of fluvoxamine for COVID-19 and long COVID

  2023cites this paper
• SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids

  2023cites this paper
• Journal Pre-proof Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: A systematic review and meta-analysis

  2023cites this paper
• The Sigma Receptors in Alzheimer’s Disease: New Potential Targets for Diagnosis and Therapy

  2023cites this paper
• The effect of SSRIs on fear learning: a systematic review and meta-analysis

  2023cites this paper
• Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study

  2022influential citation
• Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study

  2022cites this paper
• Mechanisms of action of fluvoxamine for COVID-19: a historical review

  2022cites this paper
• Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research

  2022cites this paper
• Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence?

  2022cites this paper
• Sigma-1 receptor: A potential target for the development of antidepressants.

  2022cites this paper
• Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease

  2022cites this paper
• Synthesis and characterization of the two enantiomers of a chiral sigma-1 receptor radioligand: (S)-(+)- and (R)-(-)-[18F]FBFP

  2022cites this paper
• Association between Functional Inhibitors of Acid Sphingomyelinase and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: results from an observational multicenter study

  2021cites this paper
• Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor

  2021cites this paper
• Association between Psychotropic Medications Functionally Inhibiting Acid Sphingomyelinase and reduced risk of Intubation or Death among Individuals with Mental Disorder and Severe COVID-19: an Observational Study

  2021cites this paper
• Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19?

  2021cites this paper
• Pharmacokinetics and brain σ1 receptor occupancy of MR309, a selective σ1 receptor antagonist

  2021cites this paper
• Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID‐19: An Observational Multicenter Study

  2021cites this paper
• Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?

  2021cites this paper
• Sigma-1 receptor ligands improves ventricular repolarization-related ion remodeling in rats with major depression disorder

  2020cites this paper
• Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms

  2020cites this paper
• PET Imaging of Sigma1 Receptors

  2020cites this paper
• Positron Emission Tomography Imaging Evaluation of a Novel 18F-Labeled Sigma-1 Receptor Radioligand in Cynomolgus Monkeys.

  2020cites this paper
• Synthesis and evaluation of new 1-oxa-8-azaspiro[4.5]decane derivatives as candidate radioligands for sigma-1 receptors.

  2020cites this paper
• Probing the characteristics and biofunctional effects of disease-affected cells and drug response via machine learning applications

  2020cites this paper
• In vitro and in vivo sigma 1 receptor imaging studies in different disease states.

  2020cites this paper
• Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.

  2020cites this paper
• A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine

  2019cites this paper
• Imaging sigma receptors in the brain: New opportunities for diagnosis of Alzheimer's disease and therapeutic development.

  2019cites this paper
• Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?

  2019cites this paper
• 18 F-Labeled benzylpiperazine derivatives as highly selective ligands for imaging σ1 receptor with positron emission tomography.

  2019cites this paper
• Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process

  2018cites this paper
• Occupancy of adenosine A2A receptors by istradefylline in patients with Parkinson's disease using 11C‐preladenant PET

  2018cites this paper
• Tactics for preclinical validation of receptor-binding radiotracers.

  2017cites this paper
• APEX2-enhanced electron microscopy distinguishes sigma-1 receptor localization in the nucleoplasmic reticulum.

  2017cites this paper
• 1-(4-[18F]Fluorobenzyl)-4-[(tetrahydrofuran-2-yl)methyl]piperazine: A Novel Suitable Radioligand with Low Lipophilicity for Imaging σ1 Receptors in the Brain.

  2017cites this paper
• Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection.

  2017cites this paper
• The Role of Thrombocyte Serotonin System and Some Thrombocyte Characteristics in Treatment of Depressive Patients with Cardiovascular Diseases

  2017cites this paper
• Role of σ1 Receptors in Learning and Memory and Alzheimer's Disease-Type Dementia.

  2017cites this paper
• Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders.

  2017cites this paper
• Hyperactivity of Hypothalamic-Pituitary-Adrenal Axis Due to Dysfunction of the Hypothalamic Glucocorticoid Receptor in Sigma-1 Receptor Knockout Mice

  2017cites this paper
• Anti‐anhedonic effect of selective serotonin reuptake inhibitors with affinity for sigma‐1 receptors in picrotoxin‐treated mice

  2017cites this paper
• APEX2-enhanced electron microscopy distinguishes sigma-1 receptor localization in the nucleoplasmic reticulum

  2017cites this paper
• Medicinal Chemistry of σ1 Receptor Ligands: Pharmacophore Models, Synthesis, Structure Affinity Relationships, and Pharmacological Applications.

  2017cites this paper
• Psychopharmacology of combined activation of the serotonin1A and &sgr;1 receptors

  2017cites this paper
• Involvement of GABAA receptors in 5-HT1A and σ1 receptor synergism on prefrontal dopaminergic transmission under circulating neurosteroid deficiency

  2016cites this paper
• Resolution of Pathological Skin Picking With Fluvoxamine in a 74-Year-Old Dementia Patient.

  2016cites this paper
• reportSigma-1 receptor agonist fluvoxamine for delirium in intensive care units : report of five cases

  2015cites this paper
• Role of the 5-HT1A autoreceptor in the enhancement of fluvoxamine-induced increases in prefrontal dopamine release by adrenalectomy/castration in mice.

  2015cites this paper
• Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication.

  2015cites this paper
• reportFluvoxamine for blonanserin-associated akathisia in patients with schizophrenia : report of five cases

  2015cites this paper
• AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease

  2015cites this paper
• Cutamesine Overcomes REM Sleep Deprivation-Induced Memory Loss: Relationship to Sigma-1 Receptor Occupancy

  2015cites this paper
• [Cardioprotective effect of the selective sigma-1 receptor agonist, SA4503].

  2014cites this paper
• Synthesis and characterization of poly[N-isopropylacrylamide-co-1-(N,N-bis-carboxymethyl)amino-3-allylglycerol] grafted to magnetic nano-particles for the extraction and determination of fluvoxamine in biological and pharmaceutical samples.

  2014cites this paper
• Radiosynthesis and in vivo evaluation of a novel σ1 selective PET ligand.

  2014cites this paper
• Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells.

  2014cites this paper
• Sharpless asymmetric dihydroxylation as the key step in the enantioselective synthesis of spirocyclic σ1 receptor ligands

  2014cites this paper
• Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders

  2014cites this paper
• Distinctive In Vivo Kinetics of the New σ1 Receptor Ligands (R)-(+)- and (S)-(–)-18F-Fluspidine in Porcine Brain

  2014cites this paper
• Sigma-1 Receptor Imaging in the Brain

  2014cites this paper
• Novel cyclopentadienyl tricarbonyl (99m)tc complexes containing 1-piperonylpiperazine moiety: potential imaging probes for sigma-1 receptors.

  2014cites this paper
• Brain Imaging of Sigma Receptors

  2014cites this paper
• Automation of the radiosynthesis and purification procedures for [18F]Fluspidine preparation, a new radiotracer for clinical investigations in PET imaging of σ(1) receptors in brain.

  2014cites this paper
• Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression.

  2013cites this paper
• Stimulation of σ1-receptor restores abnormal mitochondrial Ca²⁺ mobilization and ATP production following cardiac hypertrophy.

  2013cites this paper
• Neuropharmacologic studies on the brain serotonin1A receptor using the selective agonist osemozotan.

  2013cites this paper
• Sigma-1 Receptor Enhances Neurite Elongation of Cerebellar Granule Neurons via TrkB Signaling

  2013cites this paper
• Molecular imaging of σ1 receptors in vivo: current status and perspectives.

  2013cites this paper
• Synthesis and evaluation of novel (18)F-labeled spirocyclic piperidine derivatives as σ1 receptor ligands for positron emission tomography imaging.

  2013cites this paper
• Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials

  2013cites this paper
• Design and synthesis of polycyclic amine derivatives for sigma receptor activity

  2013cites this paper
• The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET).

  2013cites this paper
• Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases

  2013cites this paper
• New positron emission tomography (PET) radioligand for imaging σ-1 receptors in living subjects.

  2012cites this paper
• Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases.

  2012cites this paper
• Duloxetine-Associated Tardive Dyskinesia Resolved With Fluvoxamine A Case Report

  2012cites this paper
• Emerging drugs for major depressive disorder: an update

  2012cites this paper
• An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan.

  2012cites this paper
• A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia: A Preliminary Study

  2012cites this paper
• Application of [¹¹C]SA4503 to selection of novel σ₁ selective agonists.

  2012cites this paper
• [Cardioprotective effect of fluvoxamine, sigma-1 receptor high affinity agonist].

  2012cites this paper
• Roles of σ1 receptors in the mechanisms of action of CNS drugs

  2012cites this paper
• Re-evaluation of in vivo selectivity of [(11)C]SA4503 to σ(1) receptors in the brain: contributions of emopamil binding protein.

  2012cites this paper
• Beneficial Effects of Fluvoxamine for Chorea in a Patient With Huntington's Disease: A Case Report.

  2012cites this paper
• Duloxetine-associated tardive dyskinesia resolved with fluvoxamine: a case report.

  2012cites this paper
• Synthesis, radioiodination and in vitro and in vivo sigma receptor studies of N-1-allyl-N´-4-phenethylpiperazine analogs.

  2012cites this paper